tetano
Editor, Senior Moderator
Nat Commun
. 2023 Jul 11;14(1):4117.
doi: 10.1038/s41467-023-39560-9. Intranasal influenza-vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response in hamsters
Liang Zhang[SUP] #[/SUP][SUP] 1 [/SUP], Yao Jiang[SUP] #[/SUP][SUP] 1 [/SUP], Jinhang He[SUP] #[/SUP][SUP] 1 [/SUP], Junyu Chen[SUP] #[/SUP][SUP] 1 [/SUP], Ruoyao Qi[SUP] #[/SUP][SUP] 1 [/SUP], Lunzhi Yuan[SUP] #[/SUP][SUP] 1 [/SUP], Tiange Shao[SUP] #[/SUP][SUP] 2 [/SUP], Hui Zhao[SUP] #[/SUP][SUP] 3 [/SUP], Congjie Chen[SUP] 1 [/SUP], Yaode Chen[SUP] 1 [/SUP], Xijing Wang[SUP] 1 [/SUP], Xing Lei[SUP] 1 [/SUP], Qingxiang Gao[SUP] 4 [/SUP], Chunlan Zhuang[SUP] 1 [/SUP], Ming Zhou[SUP] 1 [/SUP], Jian Ma[SUP] 1 [/SUP], Wei Liu[SUP] 1 [/SUP], Man Yang[SUP] 1 [/SUP], Rao Fu[SUP] 1 [/SUP], Yangtao Wu[SUP] 1 [/SUP], Feng Chen[SUP] 1 [/SUP], Hualong Xiong[SUP] 1 [/SUP], Meifeng Nie[SUP] 1 [/SUP], Yiyi Chen[SUP] 1 [/SUP], Kun Wu[SUP] 1 [/SUP], Mujin Fang[SUP] 1 5 [/SUP], Yingbin Wang[SUP] 1 5 [/SUP], Zizheng Zheng[SUP] 1 5 [/SUP], Shoujie Huang[SUP] 1 5 [/SUP], Shengxiang Ge[SUP] 1 5 [/SUP], Shih Chin Cheng[SUP] 4 [/SUP], Huachen Zhu[SUP] 6 7 [/SUP], Tong Cheng[SUP] 1 5 [/SUP], Quan Yuan[SUP] 1 5 [/SUP], Ting Wu[SUP] 8 9 [/SUP], Jun Zhang[SUP] 10 11 [/SUP], Yixin Chen[SUP] 12 13 [/SUP], Tianying Zhang[SUP] 14 15 [/SUP], Changgui Li[SUP] 16 [/SUP], Hai Qi[SUP] 17 [/SUP], Yi Guan[SUP] 18 19 [/SUP], Ningshao Xia[SUP] 20 21 [/SUP]
Affiliations
The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants and "anatomical escape" characteristics threaten the effectiveness of current coronavirus disease 2019 (COVID-19) vaccines. There is an urgent need to understand the immunological mechanism of broad-spectrum respiratory tract protection to guide broader vaccines development. Here we investigate immune responses induced by an NS1-deleted influenza virus vectored intranasal COVID-19 vaccine (dNS1-RBD) which provides broad-spectrum protection against SARS-CoV-2 variants in hamsters. Intranasal delivery of dNS1-RBD induces innate immunity, trained immunity and tissue-resident memory T cells covering the upper and lower respiratory tract. It restrains the inflammatory response by suppressing early phase viral load post SARS-CoV-2 challenge and attenuating pro-inflammatory cytokine (Il6, Il1b, and Ifng) levels, thereby reducing excess immune-induced tissue injury compared with the control group. By inducing local cellular immunity and trained immunity, intranasal delivery of NS1-deleted influenza virus vectored vaccine represents a broad-spectrum COVID-19 vaccine strategy to reduce disease burden.
. 2023 Jul 11;14(1):4117.
doi: 10.1038/s41467-023-39560-9. Intranasal influenza-vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response in hamsters
Liang Zhang[SUP] #[/SUP][SUP] 1 [/SUP], Yao Jiang[SUP] #[/SUP][SUP] 1 [/SUP], Jinhang He[SUP] #[/SUP][SUP] 1 [/SUP], Junyu Chen[SUP] #[/SUP][SUP] 1 [/SUP], Ruoyao Qi[SUP] #[/SUP][SUP] 1 [/SUP], Lunzhi Yuan[SUP] #[/SUP][SUP] 1 [/SUP], Tiange Shao[SUP] #[/SUP][SUP] 2 [/SUP], Hui Zhao[SUP] #[/SUP][SUP] 3 [/SUP], Congjie Chen[SUP] 1 [/SUP], Yaode Chen[SUP] 1 [/SUP], Xijing Wang[SUP] 1 [/SUP], Xing Lei[SUP] 1 [/SUP], Qingxiang Gao[SUP] 4 [/SUP], Chunlan Zhuang[SUP] 1 [/SUP], Ming Zhou[SUP] 1 [/SUP], Jian Ma[SUP] 1 [/SUP], Wei Liu[SUP] 1 [/SUP], Man Yang[SUP] 1 [/SUP], Rao Fu[SUP] 1 [/SUP], Yangtao Wu[SUP] 1 [/SUP], Feng Chen[SUP] 1 [/SUP], Hualong Xiong[SUP] 1 [/SUP], Meifeng Nie[SUP] 1 [/SUP], Yiyi Chen[SUP] 1 [/SUP], Kun Wu[SUP] 1 [/SUP], Mujin Fang[SUP] 1 5 [/SUP], Yingbin Wang[SUP] 1 5 [/SUP], Zizheng Zheng[SUP] 1 5 [/SUP], Shoujie Huang[SUP] 1 5 [/SUP], Shengxiang Ge[SUP] 1 5 [/SUP], Shih Chin Cheng[SUP] 4 [/SUP], Huachen Zhu[SUP] 6 7 [/SUP], Tong Cheng[SUP] 1 5 [/SUP], Quan Yuan[SUP] 1 5 [/SUP], Ting Wu[SUP] 8 9 [/SUP], Jun Zhang[SUP] 10 11 [/SUP], Yixin Chen[SUP] 12 13 [/SUP], Tianying Zhang[SUP] 14 15 [/SUP], Changgui Li[SUP] 16 [/SUP], Hai Qi[SUP] 17 [/SUP], Yi Guan[SUP] 18 19 [/SUP], Ningshao Xia[SUP] 20 21 [/SUP]
Affiliations
- PMID: 37433761
- DOI: 10.1038/s41467-023-39560-9
The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants and "anatomical escape" characteristics threaten the effectiveness of current coronavirus disease 2019 (COVID-19) vaccines. There is an urgent need to understand the immunological mechanism of broad-spectrum respiratory tract protection to guide broader vaccines development. Here we investigate immune responses induced by an NS1-deleted influenza virus vectored intranasal COVID-19 vaccine (dNS1-RBD) which provides broad-spectrum protection against SARS-CoV-2 variants in hamsters. Intranasal delivery of dNS1-RBD induces innate immunity, trained immunity and tissue-resident memory T cells covering the upper and lower respiratory tract. It restrains the inflammatory response by suppressing early phase viral load post SARS-CoV-2 challenge and attenuating pro-inflammatory cytokine (Il6, Il1b, and Ifng) levels, thereby reducing excess immune-induced tissue injury compared with the control group. By inducing local cellular immunity and trained immunity, intranasal delivery of NS1-deleted influenza virus vectored vaccine represents a broad-spectrum COVID-19 vaccine strategy to reduce disease burden.